Microsphere technology: Hype or help?

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 5, 2011, Pages 27-31

  Kircik, Leon H ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Physicians Skin Care PLLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN; MICROSPHERE; RETINOIC ACID;

ACNE; ANTIBIOTIC RESISTANCE; ARTICLE; BURNING SENSATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHEMA; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRURITUS; SKIN IRRITATION;

EID: 79958286726     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Goodman G. Acne and acne scarring-the case for active and early intervention. Aust Fam Physician. 2006;35(7):503-504.
2. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis. 1998;61(2 Suppl):11-21.
3. Feldman SR. Approaching psoriasis differently: patient-physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol. 2010;9(8):908-911.
4. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20(4):370-379.
5. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol. 2006;7:231-236.
6. Zaenglein AL. Making the case for early treatment of acne. Clin Pediatr (Phila). 2010;49(1):54-59.
7. Balkrishnan R, Kulkarni AS, Cayce K, Feldman SR. Predictors of healthcare outcomes and costs related to medication use in patients with acne in the United States. Cutis. 2006;77(4):251-255.
8. Kircik, LH, Bikowski JB, Cohen DE, et al. Vehicles matter, Vol 1. Practical Dermatology. 2010;7(6 Suppl):1-16.
9. Gollnick H, Cunliffe W, Berson D, et al, Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1-S37.
10. Thiboutot D, Gollnick H, Bettoli V, et al, Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1-S50.
11. Ghali F, Kang S, Leyden J, et al. Changing the face of acne therapy. Cutis. 2009;83(2 Suppl):4-15.
12. Del Rosso JQ. Selection of therapy for acne vulgaris: balancing concerns about antibiotic resistance. Cutis. 2008;82(5 Suppl):12-16.
13. Dréno B, Thiboutot D, Gollnick H, et al, Global Alliance to Improve Outcomes in Acne. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448-456.
14. Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13(5):575-588.
15. Chadawar V, Shaji J. Microsponge delivery system. Curr Drug Deliv. 2007;4(2):123-129.
16. Jelvehgari M, Siahi-Shadbad MR, Azarmi S, Martin GP, Nokhodchi A. The microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int J Pharm. 2006;308(1-2):124-32.
17. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat. 2001;12(3):149-157.
18. Leyden JJ, Grossman R, Nighland M. Cumulative irritation potential of topical retinoid formulations. J Drugs Dermatol. 2008;7(8 Suppl):S14-S18.
19. Berger R, Rizer R, Barba A, et al. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial. Clin Ther. 2007;29(6):1086-1097.
20. Nyirady J, Lucas C, Yusuf M, Mignone P, Wisniewski S. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis. 2002;70(5):295-298.
21. Nighland M, Yusuf M, Wisniewski S, Huddleston K, Nyirady J. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis. 2006;77(5):313-316.
22. Pariser D, Bucko A, Fried R, et al. Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimen. J Drugs Dermatol. 2010;9(7):805-813.
23. Nyirady J, Nighland M, Payonk G, et al. A comparative evaluation of tretinoin gel microsphere, 0.1%, versus tretinoin cream, 0.025%, in reducing facial shine. Cutis. 2000;66(2):153-156.
24. Fakhouri T, Yentzer BA, Feldman SR. Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. J Drugs Dermatol. 2009;8(7):657-661.
25. Wester RC, Patel R, Nacht S, et al. Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. J Am Acad Dermatol. 1991;24(5 Pt 1):720-726.
26. Nokhodchi A, Jelvehgari M, Siahi MR, Mozafari MR. Factors affecting the morphology of benzoyl peroxide microsponges. Micron. 2007;38(8):834-840.
27. Bikowski J, Del Rosso JQ. Benzoyl peroxide microsphere cream as monotherapy and combination treatment of acne. J Drugs Dermatol. 2008;7(6):590-595.
28. Smith SR, Kempers S. A study of 5.5% benzoyl peroxide microsphere cream versus 6% benzoyl peroxide gel in the treatment of acne vulgaris. Cosmet Dermatol. 2006;19:537-542.
29. Del Rosso JQ, Kircik L. Comparison of the tolerability of benzoyl peroxide microsphere cream wash versus gentle cleanser when used in combination with clindamycin and tretinoin gel: a multicenter, investigator-blind, randomized study. Poster presented at: American Academy of Dermatology 67th Annual Meeting; San Francisco, California; March 6-10, 2009.
30. Del Rosso JQ. Benzoyl peroxide formulations: what is the science supporting microsphere vehicle technology and clinical use. J Clin Aesthet Dermatol. 2009;2(9):46-54.